SCHEMBL17119641

SCHEMBL17119641

OCc1cnc(Cl)cc1Nc1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 2/20 0.42
▸ SMARCA2 P51531 1/20 0.41
▸ SMARCA4 P51532 1/20 0.41
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ MAP4K4 O95819 2/20 0.36
▸ TGFBR1 P36897 1/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421499 0.86 ALDH1A1 (0.39) RECQLMAPK1CDK2KDM4EL3MBTL1
SCHEMBL17119648 0.84 KDM4E (0.40) RECQLLMNAMAPK1CCNA2CDK2
SCHEMBL17119642 0.75 GRIK1 (0.47) SMARCA2SMARCA4MEN1KMT2A
SCHEMBL17119639 0.74 SMARCA2 (0.42) ADRA2ASMARCA2SMARCA4ADRA2BADRA2C
SCHEMBL1521667 0.74 PDXK (0.38) RECQLLMNAKDM4EMEN1KMT2A
SCHEMBL29765350 0.74 PDXK (0.38) RECQLLMNAKDM4EMEN1KMT2A
SCHEMBL17119640 0.71 SMARCA2 (0.43) SMARCA2SMARCA4TGFBR1LMNAMAPK1
SCHEMBL29848036 0.71 PDXK (0.36) RECQLLMNAKDM4EL3MBTL1PDXK
SCHEMBL4281181 0.71 PDXK (0.36) RECQLLMNAKDM4EL3MBTL1PDXK
SCHEMBL17119688 0.71 CYP2C19 (0.39) RECQLMAP4K4MKNK1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-9714247-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2017-07-25 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-04-20 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-9493454-B2 Multiple kinase pathway inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MANNKIND CORPORATION 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266870-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 ADRA2A 4450/4885SMARCA2 1880/4885SMARCA4 2029/4885
US-20170107215-A1 MULTIPLE KINASE PATHWAY INHIBITORS MAP3K6, MAP3K2, MAP3K1 ADRA2A 4450/4885SMARCA2 1880/4885SMARCA4 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback